Home » Stocks » CEMI

Chembio Diagnostics, Inc. (CEMI)

Stock Price: $2.82 USD -0.12 (-4.08%)
Updated Jul 29, 2021 11:23 AM EDT - Market open
Market Cap 55.81M
Revenue (ttm) 34.33M
Net Income (ttm) -25.02M
Shares Out 20.30M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE 6.72
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $2.82
Previous Close $2.94
Change ($) -0.12
Change (%) -4.08%
Day's Open 2.93
Day's Range 2.78 - 2.94
Day's Volume 1,564,328
52-Week Range 2.06 - 8.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Why investors are watching these 3 biotech penny stocks right now The post Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other stocks mentioned: AZRX, XBIO
2 days ago - PennyStocks

HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will rele...

6 days ago - GlobeNewsWire

Chembio Diagnostics Inc. (NASDAQ:CEMI) shares rallied higher Thursday after the company received a $4 million HIV test purchase order from the Partnership for Supply Chain Management, supported by the G...

6 days ago - Benzinga

Chembio Diagnostics Inc (NASDAQ: CEMI) has received a $4 million purchase order from the Partnership for Supply Chain Management (PFSCM), supported by The Global Fund. The order comes to purchase Chembi...

6 days ago - Benzinga

HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $...

6 days ago - GlobeNewsWire

Chembio Diagnostics (NASDAQ:CEMI) shares are trading higher after the company announced it received a $28.3 million purchase order from Bio-Manguinhos for its DPP SARS-CoV-2 antigen tests in Brazil. “We...

1 week ago - Benzinga

CEMI stock is soaring after inking its first multi-million dollar sales contract for its FDA-approved Covid-19 rapid antigen test. The post CEMI Stock: $28M Covid Test Order Sends Chembio Diagnostics Sk...

1 week ago - InvestorPlace

Penny stocks to buy according to Wall Street analysts. But are they worth the risk?

Other stocks mentioned: HUT, UUUU
1 week ago - PennyStocks

Chembio Diagnostics Inc (NASDAQ: CEMI) received a $28.3 million purchase order from Brazil's Bio-Manguinhos to purchase Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021.  The Antigen test...

1 week ago - Benzinga

HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $...

1 week ago - GlobeNewsWire

HAUPPAUGE, N.Y., May 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results f...

2 months ago - GlobeNewsWire

HAUPPAUGE, N.Y., April 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will rel...

3 months ago - GlobeNewsWire

CEMI stock is soaring today after the company announced the commercial launch of a rapid Covid-19 test that was met with significant optimism. The post CEMI Stock: One Huge Reason Chembio Is Rocketing H...

3 months ago - InvestorPlace

Chembio Diagnostics Inc (NASDAQ: CEMI) shares are trading higher by 41% in Monday's pre-market session after the company announced the commercial launch of a test to differentiate between COVID-19 and t...

Other stocks mentioned: NNOX
3 months ago - Benzinga

In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes In-licensed Rapid Point-of-Care Test Available for Use i...

3 months ago - GlobeNewsWire

HAUPPAUGE, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results...

4 months ago - GlobeNewsWire

HAUPPAUGE, N.Y., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will rele...

5 months ago - GlobeNewsWire

HAUPPAUGE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Chembio Diagnostics (CEMI) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

HAUPPAUGE, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded...

7 months ago - GlobeNewsWire

In this article we will take a look at whether hedge funds think Chembio Diagnostics Inc (NASDAQ:CEMI) is a good investment right now. We check hedge fund and billionaire investor sentiment before delvi...

8 months ago - Insider Monkey

HAUPPAUGE, N.Y., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiar...

8 months ago - GlobeNewsWire

Chembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

HAUPPAUGE, N.Y., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results ...

8 months ago - GlobeNewsWire

HAUPPAUGE, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will rele...

9 months ago - GlobeNewsWire

Rapid Test Provides Results in Only 20 Minutes Rapid Test Provides Results in Only 20 Minutes

9 months ago - GlobeNewsWire

First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patient Sample First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patie...

9 months ago - GlobeNewsWire

Investors need to pay close attention to Chembio (CEMI) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

New Antibody Test System Provides Results in 15 Minutes from Finger Stick, Venous Whole Blood, Plasma, or Serum Samples New Antibody Test System Provides Results in 15 Minutes from Finger Stick, Venous ...

10 months ago - GlobeNewsWire

Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Los Angeles, California--(Newsfile Corp. - August 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnosti...

11 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ch...

11 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - August 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnosti...

11 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - August 14, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc.

11 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed...

11 months ago - Business Wire

PHILADELPHIA, Aug. 14, 2020 /PRNewswire/ -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Chembio Diagnostics, Inc.

11 months ago - PRNewsWire

RADNOR, Pa.--(BUSINESS WIRE)---- $CEMI #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP reminds Chembio Diagnostics, Inc.

11 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - August 13, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnost...

11 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #CEMI--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States Dis...

11 months ago - Business Wire

New York, New York--(Newsfile Corp. - August 12, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Chembio Diagnostics, Inc.

11 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - August 12, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnost...

11 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc. ("Chembio" or "the Company") (NASDAQ: CEMI) a...

11 months ago - Business Wire

Chembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

RADNOR, Pa., Aug. 7, 2020 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Chembio Diagnostics, Inc.

11 months ago - PRNewsWire

NEW YORK, July 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Chembio Diagnostics, Inc. (NASDAQ: CEMI) between March 12, 2020 and Jun...

1 year ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 27, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Chembio Diagnostics, Inc.

1 year ago - Newsfile Corp

RADNOR, Pa., July 24, 2020 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Chembio Diagnostics, Inc.

1 year ago - PRNewsWire

HAUPPAUGE, N.Y., July 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will re...

1 year ago - GlobeNewsWire

Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

About CEMI

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 18, 2000
Stock Exchange
NASDAQ
Ticker Symbol
CEMI
Full Company Profile

Financial Performance

In 2020, CEMI's revenue was $32.47 million, a decrease of -5.79% compared to the previous year's $34.46 million. Losses were -$25.52 million, 86.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CEMI stock is "Buy." The 12-month stock price forecast is 8.00, which is an increase of 183.69% from the latest price.

Price Target
$8.00
(183.69% upside)
Analyst Consensus: Buy